
Integrating Mpox Care and Prevention into STI Services


Hilary Reno, MD PhD FIDSA Associate Professor, Washington University in St. Louis



### Disclosures

Disclosure: Dr. Reno has no financial interest to disclose.

This continuing education activity is managed by The St. Louis STI/HIV Prevention Training Center and accredited by Missouri State Medical Association (MSMA) in cooperation with the Chicago Department of Public Health



## **Mpox: Orthopoxvirus**

- Discovered in 1958 in colonies of monkeys in a research setting.
- First case in humans was reported in 1970
  - Clade I with 10% mortality
  - Clade II with <1% mortality</li>
  - Worse outcomes in those with compromised immune systems, < 1 years old, pregnant, history of eczema
- And then in 2017, mpox cases were being diagnosed in Nigeria.

# He discovered the origin of the monkeypox outbreak — and tried to warn the world

Updated July 29, 2022 · 5:04 PM ET 

Heard on Morning Edition













RESEARCH ARTICLE

The 2017 human monkeypox outbreak in Nigeria—Report of outbreak experience and response in the Niger Delta University Teaching Hospital, Bayelsa State, Nigeria

Dimie Ogoina 1\*, James Hendris Izibewule 2, Adesola Ogunleye 4, Ebi Ederiane 5, Uchenna Anebonam 2, Aworabhi Neni 4, Abisoye Oyeyemi 5, Ebimitula Nicholas Etebu 4, Chikwe Ihekweazu 2

Dr. Dimie Ogoina





#1 ON TRENDING


Monkeypox: Last Week Tonight with John Oliver (HBO)







### **Mpox: Orthopoxvirus**



Cases in 2017 in Nigeria (after 40 years)

2018-2021: sporadic travel and animal related cases

May 2022: new outbreak reported in Europe → global

July 2022: WHO declares a public health emergency of international concern

August 2022: US Admin declares public health emergency

U.S. cases

U.S. Cases


**Total Cases** 

30,361

U.S. Deaths

**Total Deaths** 


42





### Skin Rash Presentations – 2022 Mpox Outbreak









# Mucosal and genital lesions







#### Daily Mpox Cases and 7 Day Daily Average





### Key Characteristics of MPox

**Epidemiology** 

#1: Transmission

#2: High rate of co-infections

#3: Where patients were presenting

Clinical presentations

TABLE 1. Characteristics of persons with monkeypox — United States, May 17–July 22, 2022

Characteristic (no. with available information)	No. (%)*
Total	1,195 (100)
Gender identity (1,195)	
Man	1,178 (98.7)
Transgender man	3 (0.3)
Woman	5 (0.4)
Transgender woman	5 (0.4)
Prefer not to answer	4 (0.3)
Missing	0 (—)
Race and ethnicity (1,054)	
Asian, non-Hispanic	48 (4.6)
Black, non-Hispanic	276 (26.2)
White, non-Hispanic	428 (40.6)
Hispanic	296 (28.1)
Multiple races, non-Hispanic	6 (0.6)
Missing	141

Philpott D, Hughes CM, Alroy KA, et al. Epidemiologic and Clinical Characteristics of Monkeypox Cases — United States, May 17— July 22, 2022. MMWR Morb Mortal Wkly Rep 2022;71:1018-1022

Key Epi finding #1: Transmission

<sup>\*</sup> Percentages calculated using nonmissing data.

#### Clinical Infectious Diseases










# Is Mpox a Sexually Transmitted Infection? Why Narrowing the Scope of This Disease May Be Harmful

Aniruddha Hazra<sup>1</sup> and Joseph N. Cherabie<sup>2</sup>

<sup>1</sup>Section of Infectious Diseases and Global Health, University of Chicago Medicine, Chicago, Illinois, USA; and <sup>2</sup>Division of Infectious Diseases, Washington University School of Medicine—St. Louis, St. Louis, Missouri, USA

## Key Epi finding #2: Co-infections



Interim Guidance for Prevention and Treatment of Monkeypox in Persons with HIV Infection — United States, August 2022

28-51% cases are co-infected with HIV

The NEW ENGLAND JOURNAL of MEDICINE

#### ORIGINAL ARTICLE

Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022

J.P. Thornhill, S. Barkati, S. Walmsley, J. Rockstroh, A. Antinori, L.B. Harrison, R. Palich, A. Nori, I. Reeves, M.S. Habibi, V. Apea, C. Boesecke, L. Vandekerckhove, M. Yakubovsky, E. Sendagorta, J.L. Blanco, E. Florence, D. Moschese, F.M. Maltez, A. Goorhuis, V. Pourcher, P. Migaud, S. Noe, C. Pintado, F. Maggi, A.-B.E. Hansen, C. Hoffmann, J.I. Lezama, C. Mussini, A.M. Cattelan, K. Makofane, D. Tan, S. Nozza, J. Nemeth, M.B. Klein, and C.M. Orkin, for the SHARE-net Clinical Group\*

29% cases are co-infected with an STI

### Key finding #3: Where patients were presenting

Surveillance

Education: public and health

systems

Messaging: Interrupt transmission

Resource deployment: Testing,

Treatment, etc

STI clinics

ED/ Urgent Cares

Primary Care Hospitalizations were usually for pain control

## Key clinical lesions we cannot forget

#### INFECTIONS CAUSING DIFFUSE RASHES

- Syphilis
- Varicella/VZV
- Disseminated herpes
- Molluscum contagiosum
- Disseminated fungal infections
- Disseminated gonococcal infection

#### Coxsackie Virus (HFM)

#### **NON INFECTIOUS**

(less common)

- Recurrent aphthous stomatitis
- Behcet's Disease
- Trauma
- Squamous cell carcinoma
- Drug-induced
- Other

#### **PROCTITIS**

- Chlamydia including LGV serovars
- Gonorrhea
- HSV
- Syphilis


#### **ULCERATIVE STIS**

- Herpes simplex virus
- Syphilis
- Chancroid
- Lymphogranuloma venereum (LGV)
- Granuloma Inguinale

## Avoid Missed Opportunities: Needed Work

#### Public Health must remain adaptable.

- Sexual health is health care.
  - Encourage clinicians to take a sexual history.
- Co-infection rates were high (HIV, STIs)
  - Syndemic approach means offering STI prevention including vaccination alongside STI testing and care.
- Continuing to improve care for populations most impacted
  - Trauma informed and culturally aware care.
  - Partner and share information with clinical systems, outpatient clinics, urgent cares, etc.







# Testing

- Remember this is a dry collection tube
- Contrasts with GC culture (which we all need to have access to).

### Medical Countermeasures







**JYNNEOS** 


**Tecovirimat (TPOXX)** 

Vaccinia immune globulin

**ACAM2000** 

**Cidofovir** 

Brincidofovir



### Study of Tecovirimat for Human Monkeypox Virus (STOMP)

- Started enrollment September 2022
- "Randomized, placebo-controlled, double-blind study to establish the efficacy of tecovirimat for the treatment of people with laboratory-confirmed or presumptive HMPXV disease."
- Goal: 530 participants
- Outcome: Time to clinical resolution of lesions

### Study of Tecovirimat for Human Monkeypox Virus (STOMP)

#### United States, Illinois

Ann & Robert H Lurie Children's Hospital of Chicago

Chicago, Illinois, United States, 60611

Contact: Ellen Chadwick, LoR 312-227-4080 egchadwick@luriechildrens.org

Northwestern University

Chicago, Illinois, United States, 60611

Contact: Babafemi Taiwo, IoR 312-695-5085 b-taiwo@northwestern.edu

Rush University Cook County Hospital Chicago NICHD CRS

Chicago, Illinois, United States, 60612

Contact: Mariam Aziz, IoR 773-551-2040 mariam\_aziz@rush.edu

Rush University CRS

Chicago, Illinois, United States, 60612

Contact: Shivanjali Shankaran, IoR 312-942-5865 Shivanjali Shankaran@rush.edu

### Public Health Work is Multi-faceted

